Background Infliximab (IFX) is effective therapy for ulcerative colitis and Crohn's disease, but
it may be associated with side effects and loss of response. One loss of response …

Background Several factors influencing the pharmacokinetics of infliximab (IFX) in
inflammatory bowel disease (IBD) have been identified. We studied the impact of patient …

Background Infliximab (IFX) is effective in the treatment of inflammatory bowel diseases
(IBD). Currently, IFX is administered at fixed doses and intervals; however, costs are high …

Background The aim of the study was to investigate variations in anti-infliximab (IFX)
antibody (Ab) levels and clinical implications thereof in patients with inflammatory bowel …

OBJECTIVES: Infliximab (IFX) is successfully used in the treatment of inflammatory bowel
diseases but some patients generate antibodies to IFX (ATI) jeopardizing the …

Background and Aims: A number of observational studies have reported an association
between serum levels of infliximab [IFX] at various thresholds, and clinical outcomes in …

Infliximab, a chimeric monoclonal antibody, has profoundly modified the treatment of several
inflammatory diseases, but no satisfactory description of its pharmacokinetics is available …

Background and Aims A significant proportion of patients with corticosteroid-refractory acute
ulcerative colitis [UC] fail therapy. We aimed to assess the pharmacokinetics [PK] of …

Infliximab was the first monoclonal antibody to be approved for the treatment of pediatric and
adult patients with moderately to severely active Crohn's disease (CD) and ulcerative colitis …

BACKGROUND: Infliximab is a chimeric monoclonal antibody against TNFα. The
pharmacokinetic (PK) properties of infliximab have been studied in several adult patient …